Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002–2011)

Cancer Communications

Rong Cao¹  Pei-An Lou²  Xin-Yu Zhu³  Yu-Qin Liu⁴  Lan-Wei Guo⁵  Li Lan⁶  Jian-Song Ren⁷  Min Dai⁸  Ya-Na Bai⁹  Kai Zhang^1,10  Jian-Gong Zhang^1,11  Xiao-Hua Sun^1,12  Guo-Xiang Liu^1,13  Qi Zhou^1,15  A-Yan Mao^1,16  Ji-Yong Gong^1,16  Shou-Ling Wu^1,17  Ying Ren^1,18  Ju-Fang Shi^1,19  Jin-Yi Zhou^1,19  Li-Hong Lv^1,19  Xiao-Jie Sun^1,19  Hui-Yao Huang^1,19  Xian-Zhen Liao^2,20  Lin Zhu^2,21  Bing-Bing Song^2,22  Xiao Qi^2,24  Xiao-Jing Xing^2,25  Ling-Bin Du^2,26  Jie He^2,27 

[1] Institute, Shenyang, P. R. China;Cancer Epidemiology Research Center, Gansu Provincial Cancer Hospital, Lanzhou, P. R. China;Center for Health Management and Policy, Key Lab of Health Economics and Policy, Shandong University, Jinan, P. R. China;Chongqing Office for Cancer Control and Research, Chongqing Cancer Hospital, Chongqing, P. R. China;Department of Cancer Epidemiology, Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, P. R. China;Department of Control and Prevention of Chronic Non-Communicable Diseases, Xuzhou Center for Disease Control and Prevention, Xuzhou, P. R. China;Department of Health Economics, School of Health Management, Harbin Medical University, Harbin, P. R. China;Department of Health Policy and Economic Research, Guangdong Provincial Institute of Public Health, Guangzhou, P. R. China;Department of Human Resources, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, P. R. China;Department of Occupational Medicine, Tangshan People’Health Department of Kailuan Group, Kailuan General Hospital, Tangshan, P. R. China;Heilongjiang Office for Cancer Control and Research, Affiliated Cancer Hospital of Harbin Medical University, Harbin, P. R. China;Hunan Office for Cancer Control and Research, Hunan Provincial Cancer Hospital, Changsha, P. R. China;Institute of Chronic Disease Prevention and Control, Harbin Center for Disease Control and Prevention, Harbin, P. R. China;Institute of Chronic Non-Communicable Diseases Prevention and Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China;Institute of Epidemiology and Health Statistics, Lanzhou University, Lanzhou, P. R. China;Liaoning Office for Cancer Control and Research, Liaoning Cancer Hospital &Ningbo Clinical Cancer Prevention Guidance Center, Ningbo NO. 2 Hospital, Ningbo, P. R. China;Program Office for Cancer Screening in Urban China, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College, National Cancer Center of China, Beijing, P. R. China;Public Health Information Research Office, Institute of Medical Information, Chinese Academy of Medical Sciences (CAMS), Beijing, P. R. China;Science and Education Department of Public Health Division, Shandong Tumor Hospital, Jinan, P. R. China;Teaching and Research Department, Affiliated Cancer Hospital of Xinjiang Medical University, ÜUrban Office of Cancer Early Detection and Treatment, Tieling Central Hospital, Tieling, P. R. China;Zhejiang Office for Cancer Control and Research, Zhejiang Cancer Hospital, Hangzhou, P. R. China;mqi, P. R. China;rüs Hospital, Tangshan, P. R. China

关键词: Esophageal neoplasms;    Medical expenditure;    Diagnosis and treatment;    China;   

DOI  :  10.1186/s40880-017-0242-3

学科分类：肿瘤学

来源: Springer

【 摘 要 】

Esophageal cancer is associated with substantial disease burden in China, and data on the economic burden are fundamental for setting priorities in cancer interventions. The medical expenditure for the diagnosis and treatment of esophageal cancer in China has not been fully quantified. This study aimed to examine the medical expenditure of Chinese patients with esophageal cancer and the associated trends. From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 37 hospitals in 13 provinces/municipalities across China as a part of the Cancer Screening Program of Urban China. For each esophageal cancer patient diagnosed between 2002 and 2011, clinical information and expense data were extracted by using structured questionnaires. All expense data were reported in Chinese Yuan (CNY; 1 CNY = 0.155 USD) based on the 2011 value and inflated using the year-specific health care consumer price index for China. A total of 14,967 esophageal cancer patients were included in the analysis. It was estimated that the overall average expenditure per patient was 38,666 CNY, and an average annual increase of 6.27% was observed from 2002 (25,111 CNY) to 2011 (46,124 CNY). The average expenditures were 34,460 CNY for stage I, 39,302 CNY for stage II, 40,353 CNY for stage III, and 37,432 CNY for stage IV diseases (P < 0.01). The expenditure also differed by the therapy type, which was 38,492 CNY for surgery, 27,933 CNY for radiotherapy, and 27,805 CNY for chemotherapy (P < 0.05). Drugs contributed to 45.02% of the overall expenditure. These conservative estimates suggested that medical expenditures for esophageal cancer in China substantially increased in the last 10 years, treatment for early-stage esophageal cancer costs less than that for advanced cases, and spending on drugs continued to account for a considerable proportion of the overall expenditure.

【 授权许可】

CC BY